Physician profile
Bridget Tan
NPI 1295233625
$4,153.23
in general payments reported to CMS, 2019-2025
34 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $740 · 2022: $690 · 2023: $732 · 2024: $819 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,723.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,384.03 | 2021-2025 | |
| Pfizer INC. | $350.68 | 2021-2025 | |
| Novo Nordisk INC | $312.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $283.62 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $219.02 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $208.11 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.33 | 2021-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $141.24 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $129.34 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.75 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $107.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $100.22 | 2021-2024 | Spravato |
| Merck Sharp & Dohme LLC | $80.29 | 2021-2025 | Vaxelis, Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $70.39 | 2024-2025 | Veozah |
| Irhythm Technologies, INC. | $66.18 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $45.89 | 2024-2025 | Immunocap |
| Biohaven Pharmaceutical Holding Company Ltd. | $38.69 | 2022 | |
| Abbott Laboratories | $38.21 | 2025 | Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $36.76 | 2022-2023 | Eliquis |
| Vbi Vaccine (Delaware) INC. | $24.98 | 2023 | Prehevbrio |
| Sumitomo Pharma America, INC. | $23.00 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $21.43 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.32 | 2021 | |
| Amgen INC. | $20.07 | 2025 | Repatha, Otezla |
| Lundbeck LLC | $19.88 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $18.00 | 2023 | Nuzyra |
| Ironwood Pharmaceuticals, INC | $17.25 | 2021 | |
| Myriad Women'S Health, INC. | $16.67 | 2023 | Myrisk |
| Novartis Pharmaceuticals Corporation | $16.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.52 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.69 | 2023 | Gvoke Hypopen |
| Cranial Technologies, INC | $13.84 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.39 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $11.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.